Search

Monday, 29th May 2023



  • Home
  • Lopez Companies
    • Business and Finance
    • Promos and Offers
  • HR Updates
    • HR Council
    • Business Excellence
    • Job Opportunities
  • Employee News
    • Message from Lopez
    • Meet the Executive
    • Meet the Team
    • Milestones
    • Spotlight
    • Advocacy
  • Corporate Sustainability
    • ABS-CBN Foundation
    • Sagip Kapamilya
    • OML Climate Change Center
    • Knowledge Channel
    • Lopez Museum
  • Lifestyle
    • Kapamilya Entertainment
    • Power Plant Mall Finds
    • ABS-CBN Publications
    • Food and Recipes
    • Lifelong Wellness
  • Lopez Values
    • 7 Lopez Values
    • The Credo
    • Web Comics
    • Special Feature

All about the vaxx

Twitter

All about the vaxxAll about the vaxxHeres a quick look at the main vaccine brands being used in Vac2Normal and in the Kapamilya Vaccination Program: AstraZeneca, Moderna and Novavax’s Covovax.

OXFORD ASTRAZENECA

Manufacturer/developer: AstraZeneca, University of Oxford (UK)

Countries with EUA: 99 countries including US, UK, Australia, Mexico, Argentina, India, Philippines

Philippine FDA EUA approval: January 28, 2021

Age group covered by FDA EUA approval: 18 years old and above

Technology platform: Viral vector (nonreplicating)

Dose and frequency: 2 doses, 4-12 weeks apart

Vaccine efficacy (VE): 70.4% overall VE against symptomatic COVID-19, 14 days after the second dose

Common adverse events reported in Phase III clinical trials: Injection site pain and tenderness, fatigue, headache, feverishness, myalgia (muscle pain)

Serious adverse events reported in Phase III clinical trials: None reported

 

MODERNA

Manufacturer/developer: Moderna, National Institute of Allergy and Infectious Diseases (US)

Countries with EUA: 49 countries with EUA approval including US, UK, EU, Switzerland, Canada, Australia, Philippines

Philippine FDA EUA approval: May 5, 2021

Age group covered by FDA EUA approval: 18 years old and above

Technology platform: mRNA

Dose and frequency: 2 doses, 28 days apart

Vaccine efficacy (VE): 94.1% overall VE against symptomatic COVID-19, occurring at least 14 days after the second dose; 100% VE against severe COVID-19

Common adverse events reported in Phase III clinical trials: Injection site pain, fatigue, headache myalgia (muscle pain), arthralgia (joint pain), chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site and erythema (skin redness/inflammation) at the injection site

Serious adverse events reported in Phase III clinical trials: Severe allergic reactions, including anaphylaxis

 

COVOVAX

Manufacturer/developer: Serum Institute of India, Novavax (US)

Countries with EUA: No EUA approvals yet

Philippine FDA EUA approval: --

Age group covered by FDA EUA approval: --

Technology platform: Protein subunit

Dose and frequency: 2 doses, 21 days apart

Vaccine efficacy (VE): Awaiting EUA application

Common adverse events reported in Phase III clinical trials: Awaiting EUA application

Serious adverse events reported in Phase III clinical trials: Awaiting EUA application (Source: doh.gov.ph)

 

Subscribe to Lopezlink

More Articles from Lopezlink

EDC, UP IB release ‘Wildlife Treasures’

EDC, UP IB release ‘Wildlife Treasures’

Accomplish your to-do list without breaking a sweat

Accomplish your to-do list without breaking a sweat

Meet the team of ABS-CBN

Meet the team of ABS-CBN

First Gen recurring earnings up by 17% to P14.8B

First Gen recurring earnings up by 17% to P14.8B

Rockwell, Asian Eye emerge as Palaro champs

Rockwell, Asian Eye emerge as Palaro champs

EDC wins gold, silver awards at 8th ASRA

EDC wins gold, silver awards at 8th ASRA

Let’s solve the learning crisis together

Let’s solve the learning crisis together

Seeing clearly after cataract surgery

Seeing clearly after cataract surgery

ABS-CBN shows return via Zoe’s A2Z Channel 11

ABS-CBN shows return via Zoe’s A2Z Channel 11

Goldlink is Maynilad’s ‘Service Provider of The Year’

Goldlink is Maynilad’s ‘Service Provider of The Year’

Milestone of SKY Fiber

SKYcable jazzes up HD plans with top channels

SKYcable jazzes up HD plans with top channels

Abigail Querubin-Aquino: ‘People first’

Abigail Querubin-Aquino: ‘People first’

FPH attributable RNI up by 34%

FPH attributable RNI up by 34%

Cebu school gets free access to Knowledge Channel via SKYdirect

Cebu school gets free access to Knowledge Channel via SKYdirect

ABS-CBN Lingkod Kapamilya Foundation

Lopez Holdings Corp. All rights reserved



About Us | Copyright | Sitemap | Archive